Aripiprazole Tablet
Product Images NDC 82804-236

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 82804-236). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (Figure 1)

A pharmacokinetic chart titled 'The Effect of Other Drugs on Aripiprazole Pharmacokinetics' showing the fold change and 90% confidence intervals for aripiprazole AUC and Cmax values. It compares the effects of various interacting drugs, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, valproate, lithium, and lorazepam, relative to a reference without interacting drugs.*

FDA Label Image

Image 2 (Figure 2)

A horizontal bar chart titled 'The Effect of Other Drugs on Dehydro-Aripiprazole Pharmacokinetics' showing fold changes and 90% confidence intervals for aripiprazole's pharmacokinetic measures (AUC and Cmax) when combined with various drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). The x-axis represents fold change relative to reference without interacting drug on a scale from 0.5 to 3.0.*

FDA Label Image

Image 3 (Figure 3)

A pharmacokinetic chart titled 'The Effect of Aripiprazole on Pharmacokinetics of Other Drugs,' showing fold change and 90% confidence intervals for various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, and venlafaxine. The x-axis represents change relative to a reference without interacting drug, ranging from 0.5 to 3.0, with plotted data points indicating effects of aripiprazole on each drug's pharmacokinetic parameters.*

FDA Label Image

Image 4 (Figure 4)

A chart illustrating the effect of intrinsic factors on aripiprazole pharmacokinetics. It compares pharmacokinetic parameters AUC and Cmax across categories including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, showing fold changes relative to a reference with 90% confidence intervals.*

FDA Label Image

Image 5 (Figure 5)

A pharmacokinetic chart titled 'Effect of Intrinsic Factors on Dehydro-aripiprazole Pharmacokinetics' showing fold change and 90% confidence intervals in dehydro-aripiprazole exposure. The x-axis represents change relative to reference, while the y-axis compares different intrinsic factors such as CYP2D6 metabolizer status, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment. The chart illustrates AUC and Cmax changes for each factor.*

FDA Label Image

Fig-6 (Figure 6)

Kaplan-Meier plot illustrating the cumulative proportion of patients with relapse over 182 days from randomization in a schizophrenia study. The graph compares aripiprazole and placebo groups, with the y-axis showing proportion with relapse and the x-axis showing days. Numbers of subjects at risk at various time points are provided below the x-axis.*

FDA Label Image

7 (Figure 7)

A Kaplan-Meier plot showing the cumulative proportion of patients with relapse over days from randomization in a bipolar study. The graph compares two groups: one treated with aripiprazole and the other with placebo. The x-axis represents days from randomization, and the y-axis shows the proportion of patients with relapse. Below the graph, a table indicates the number of subjects at risk for each group across the study duration.*

FDA Label Image

8 (Figure 8)

Kaplan-Meier curve showing the cumulative proportion of patients experiencing relapse to any mood event in a Bipolar Study over 364 days from randomization. The graph compares relapse rates between aripiprazole and placebo groups, with the proportion with relapse displayed on the vertical axis and days from randomization on the horizontal axis. Number of subjects at risk is indicated along the timeline.*

FDA Label Image

9 (Figure 9)

Line graph showing the least squares mean change from baseline in YGTSS total tic score over 8 weeks of treatment in a Tourette's Disorder study. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, illustrating decreasing tic scores over time, with the greatest reduction in the high dose group.*

FDA Label Image

82804-236-90 (Image 01)

Label for Aripiprazole 10 mg tablets, packaged in a quantity of 90. The label shows the product is relabeled by Proficient Rx LP and originally manufactured by Torrent Pharmaceuticals Ltd. It includes dosage form as round, uncoated tablets debossed with "10" and "18" on sides, storage instructions, and a barcode.*

FDA Label Image

Image (Mg Logo)

FDA Label Image

Logo (Pi Logo)

FDA Label Image

Description Image (Structure)

Chemical structure of aripiprazole, showing its molecular framework including dichlorophenyl, piperazine, and quinolinone moieties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.